Published on
May 28, 2026
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and ...
Introduction Epidermal growth factor receptor (EGFR) mutations are among the most clinically actionable drivers in non–small cell lung cancer (NSCLC), second to KRAS in prevalence.1 Classical EGFR sensitizing mutations, namely exon 19 deletions and L858R …
Source:
Dove Medical Press
-
Neutral
